Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.

An oral care composition is provided wherein the composition comprises an ionic liquid, wherein the ionic liquid comprises: a) a quaternary ammonium cation of the formula wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each an organic moiety and may be the same or different, and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 includes a hydroxyl; and b) an anion selected from the group consisting of salicylate, alkylsulfate, sulfate, acetate, halide, phosphate, alkyl phosphate and tosylate; wherein the oral care composition is a mouth rinse, toothpaste, toothpowder, oral bead or strip, fluid-encased dental strip, irrigation fluid, plaque removal liquid, dental floss, hard candy, soft candy, lozenge, chewing gum, or lollipop. ##STR00001##

An oral care composition is provided wherein the composition comprises an ionic liquid, wherein the ionic liquid comprises: a) a quaternary ammonium cation of the formula wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each an organic moiety and may be the same or different, and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 includes a hydroxyl; and b) an anion selected from the group consisting of salicylate, alkylsulfate, sulfate, acetate, halide, phosphate, alkyl phosphate and tosylate; wherein the oral care composition is a mouth rinse, toothpaste, toothpowder, oral bead or strip, fluid-encased dental strip, irrigation fluid, plaque removal liquid, dental floss, hard candy, soft candy, lozenge, chewing gum, or lollipop. ##STR00001##

An oral care composition is provided wherein the composition comprises an ionic liquid, wherein the ionic liquid comprises: a) a quaternary ammonium cation of the formula wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each an organic moiety and may be the same or different, and at least one of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 includes a hydroxyl; and b) an anion selected from the group consisting of salicylate, alkylsulfate, sulfate, acetate, halide, phosphate, alkyl phosphate and tosylate; wherein the oral care composition is a mouth rinse, toothpaste, toothpowder, oral bead or strip, fluid-encased dental strip, irrigation fluid, plaque removal liquid, dental floss, hard candy, soft candy, lozenge, chewing gum, or lollipop. ##STR00001##

The present invention relates to a method of treating a tumor in a subject. This method involves administering to a subject having a Hippo pathway mutant tumor a tankyrase inhibitor, where the tumor is susceptible to treatment with the tankyrase inhibitor, and said administering is carried out to treat the tumor. The present invention also relates to a method of treating cancer in a subject, and a method of identifying a subject as a candidate for treatment.

The present invention relates to a method of treating a tumor in a subject. This method involves administering to a subject having a Hippo pathway mutant tumor a tankyrase inhibitor, where the tumor is susceptible to treatment with the tankyrase inhibitor, and said administering is carried out to treat the tumor. The present invention also relates to a method of treating cancer in a subject, and a method of identifying a subject as a candidate for treatment.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO.sub.2.sup.−). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.